Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WD-890 in moderate to severe plaque psoriasis
NCT07672561Phase 3Recruiting
- Sponsor
- Zhejiang Wenda Pharmaceutical Technology Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
A Phase 3 trial of WD-890 in plaque psoriasis, sponsored by Zhejiang Wenda Pharmaceutical Technology Co., Ltd.. Started Mar 2026; status: recruiting.
02
Drugs
WD-890
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07672561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07672561.